

Cite this: *Chem. Sci.*, 2022, 13, 1023

All publication charges for this article have been paid for by the Royal Society of Chemistry

Photochemical C–H arylation of heteroarenes for DNA-encoded library synthesis†

Matthias Krumb, ^{‡a} Lisa Marie Kammer, ^{‡a} Shorouk O. Badir, ^a María Jesús Cabrera-Afonso, ^a Victoria E. Wu, ^b Minxue Huang, ^b Adam Csakai, ^b Lisa A. Marcaurelle ^b and Gary A. Molander ^{*a}

DNA-encoded library (DEL) technology has emerged as a time- and cost-efficient technique for the identification of therapeutic candidates in the pharmaceutical industry. Although several reaction classes have been successfully validated in DEL environments, there remains a paucity of DNA-compatible reactions that harness building blocks (BBs) from readily available substructures bearing multifunctional handles for further library diversification under mild, dilute, and aqueous conditions. In this study, the direct C–H carbonyl functionalization of medicinally-relevant heteroarenes can be accomplished *via* the photoreduction of DNA-conjugated (hetero)aryl halides to deliver reactive aryl radical intermediates in a regulated fashion within minutes of blue light illumination. A broad array of electron-rich and electron-poor heteroarene scaffolds undergo transformation in the presence of sensitive functional groups.

Received 15th October 2021
Accepted 6th December 2021


DOI: 10.1039/d1sc05683b

rsc.li/chemical-science

Introduction

The identification of potent drug candidates against novel biological targets is a critical, resource-intensive, and time-consuming challenge in the pharmaceutical industry. Although high-throughput screening (HTS),^{1–4} is routinely used to identify specific binding molecules within drug discovery efforts, a drawback of this approach is the sheer cost and extensive labor required per library member. Originally envisioned by Brenner and Lerner in 1992,⁵ DNA-encoded library (DEL) technology has been recently enlisted as an innovative interrogation format in pharmaceutical settings to overcome this limitation.^{6,7} A DEL library describes a collection of small molecule ligands covalently bound to a DNA barcode bearing the information with respect to the identity and structural composition of discrete library members. These libraries can be prepared by an initial reaction of diverse building blocks (BBs) with a short DNA sequence conjugated to an organic functional group (the DNA headpiece). This is followed by several split and pool cycles of chemistry to synthesize and simultaneously encode additional units (Scheme 1).^{8,9} Upon library completion, the generated structures are incubated against an immobilized target protein, after which the low-affinity or non-binding

ligands are washed away.^{10,11} The DNA barcode of the remaining high-affinity ligands are then amplified using polymerase chain reaction (PCR), and the corresponding chemical identities can be decoded through next generation sequencing of the DNA barcode. Using this interrogation technique, combinatorial libraries of remarkable size ($>10^6$ to 10^{12} molecules) are screened against a protein target of interest,¹² while only vanishingly small quantities of the library are used per experiment.^{13–16} Given that DEL technology is currently in its early stages of development relative to traditional HTS, it is remarkable that DEL success stories within medicinal chemistry are already known. These include the discovery of GlaxoSmithKline's inhibitor of receptor interacting protein 1 (RIP1) kinase GSK2982772 against inflammatory diseases in 2016,^{14,17} as well as AstraZeneca, Heptares Therapeutics, and X-Chem's inhibitor for protease-activated receptor 2 (PAR2) AZ3451, all fruitful outcomes of DEL screening.^{18,19} These examples emphasize the potential of DELs as readily accessible and effective screening modalities in drug discovery research.



Scheme 1 Schematic representation of DNA-encoded library construction and hit identification.

^aRoy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, PA 19104-6323, USA. E-mail: gmolandr@sas.upenn.edu

^bEncoded Library Technologies/NCE Molecular Discovery, R&D Medicinal Science and Technology, GlaxoSmithKline, 200 Cambridge Park Drive, Cambridge, MA 02140, USA

† Electronic supplementary information (ESI) available: Experimental and computational details, as well as spectral data. See DOI: 10.1039/d1sc05683b

‡ These authors contributed equally.

Although various synthetic hurdles have been addressed, the intrinsic presence of the DNA molecule poses restrictions regarding the nature of chemical transformations amenable in DELs.²⁰ In particular, strong (Lewis)-acids, oxidizing reagents, elevated temperatures, and chemical transformations requiring anhydrous and inert conditions enforce a high barrier to practical implementation in high-throughput settings. Recently, our groups and others have developed DNA-compatible reactions that harness diverse chemical feedstocks including carboxylic acids,^{21–23} (α -silyl)amines,^{24–26} 1,4-dihydropyridines (DHPs),²⁷ and alkyl bromides.^{26,28} Despite the vast chemical space available for drug discovery today,^{29,30} transformations for the assembly of $C(sp^2)$ – $C(sp^2)$ bonds remain an integral part of the toolbox of medicinal chemists.^{31,32} The development of such transformations from commodity and medically relevant BBs would further advance DEL technology (Scheme 2).

Notably, progress to achieve $C(sp^2)$ – $C(sp^2)$ cross-coupled products on DNA using (hetero)aryl halides or aryl fluorosulfonates with organoboron reagents in homogeneous or micellar systems has been reported (Scheme 2, middle).^{33–35} These procedures, however, typically require elevated temperatures or


highly activated electrophiles for the reaction to proceed under traditional palladium-catalyzed, two-electron cross-coupling conditions. To address these inherent mechanistic limitations, the rise of photoredox catalysis has provided access to alternative single-electron-transfer (SET) reaction pathways facilitating C–C and C–X bond formation *via* open shell intermediates under exceptionally mild conditions at room temperature, platforms that continue to render a significant impact in DEL settings.^{36–40}

As part of a research program centered on the development of novel synthetic methods to expand chemical space in DELs,^{12,26,27} herein we report a photochemical strategy for the assembly of $C(sp^2)$ – $C(sp^2)$ linkages using DNA-conjugated (hetero)aryl halides⁴¹ as carbon-based radical precursors (Scheme 2, bottom). This Minisci-type C–H arylation harnesses medically-relevant heteroarenes as acceptors, bypassing the need for prefunctionalization of library BBs.


Traditionally, activation of carbon–halogen bonds relies on harsh reaction conditions such as metal–halogen exchange,⁴² reaction with metal hydrides,⁴³ or transition metal-catalyzed dehalogenation reactions.^{44,45} By contrast, photoexcited transition metal complexes, such as *fac*-tris[2-phenylpyridinato- C^2,N] iridium(III) [Ir(ppy)₃], can reach powerful reduction potentials ($E_{ox}^* = -1.88$ V, $E_{red} = -2.23$ V vs. SCE⁴⁶), facilitating a direct reductive dehalogenation event of aryl electrophiles under mild conditions.⁴⁴ In this context, the photoreduction of DNA-conjugated aryl halides presents a powerful scenario to access multifunctional subunits on DNA from readily available building blocks. Although Minisci-type alkylation processes generally require protonation of the nitrogen to facilitate lowering of the LUMO energy for radical attack,⁴⁷ aryl radicals are known to undergo functionalization under neutral conditions.⁴⁸ We reasoned this reactivity profile would be ideal for on-DNA chemistries that benefit from user-friendly processes amenable to high-throughput platforms.

Discussion

Inspired by the pioneering work of Beckwith,⁴⁹ followed by seminal publications from Stephenson,⁴⁴ König,⁵⁰ and others,^{51–55} we investigated the feasibility of this photochemical proposal in DEL environments under photoredox conditions. Initial experiments were performed using on-DNA conjugated 4-fluoro-3-iodobenzoic acid (**1a**) with isoquinoline derivative **2a** as the radical acceptor in the presence of Ir(ppy)₃ under blue light irradiation (Table 1). Good conversion to the desired arylated product was observed within five minutes of blue light irradiation under open-to-air conditions (entry 1). Next, the influence of the amine reductant was investigated (entries 2–5). Although product formation was detected in the presence of triethylamine, Hantzsch ester (HE, diethyl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate), diisopropylamine (DIPA), and tetramethylethylenediamine (TMEDA), optimal reactivity was accomplished using 5.0 equivalents of *N,N*-diisopropylethylamine (DIPEA). As expected, the exclusion of photocatalyst as well as light led to no conversion (entries 14 and 15). Notably, the major side product observed under the developed



Scheme 2 Medicinally relevant heteroarene scaffolds containing (hetero)arene $C(sp^2)$ – $C(sp^2)$ bonds (top). On-DNA heteroarylation protocols using palladium two-electron cross-coupling processes (middle). This strategy: direct photochemical C–H heteroarylation through the intermediacy of aryl radicals (bottom).

Table 1 On-DNA photochemical heteroarylation of aryl halides: optimization of reaction conditions and control experiments^a


Entry	Deviation from std conditions	% Conversion ^b
1	None	60
2	Et ₃ N	56
3	Hantzsch ester	48
4	DIPA	41
5	TMEDA	43
6	1 equiv. DIPEA	57
7	10 equiv. DIPEA	51
8	20 equiv. DIPEA	41
9	0.25 equiv. Ir(ppy) ₃	60
10	1.0 equiv. Ir(ppy) ₃	56
11	0.25 equiv. Ir(ppy) ₃ + 10 equiv. DIPEA	53
12	0.10 equiv. Ir(ppy) ₃ + 15 equiv. DIPEA	43
13	No amine	34
14	No Ir(ppy) ₃	0
15	No light	0

^a Reaction conditions: DNA-conjugated aryl halide **1A** (1.0 equiv., 25 nmol), methyl isoquinoline-3-carboxylate **2a** (250 equiv., 6.25 μmol), Ir(ppy)₃ (0.5 equiv., 12.5 nmol), DIPEA (5.0 equiv., 125 nmol), 3 : 1 DMSO/H₂O (1.25 mM), 5 min irradiation with blue Kessil lamps (λ_{max} = 456 nm, 40 W). ^b Conversion to **4a** was determined by LC/MS analysis (see ESI).

conditions stems from protodehalogenation of the aryl halide formed through rapid hydrogen atom transfer (HAT). To suppress this competitive process,⁴⁴ higher loadings of the heteroarene were utilized (250 equivalents). This strategy can be quite powerful in the context of DEL reactions, which are conducted on minute scale (e.g., 10–25 nmol), rendering the chemical processes highly selective with side products that can be readily identified.

The scope of the photochemical reaction was evaluated on a broad cross-section of pharmaceutically-relevant heterocyclic space employing DNA-conjugated aryl iodide **1A** (Scheme 3). In general, successful (hetero)arylation of both electron-deficient and electron-rich heteroarenes was accomplished in the presence of structural scaffolds displaying a high density of pendant functional groups. First, the C–H carbofunctionalization of electron-deficient isoquinolines and quinolines was examined. Substitution at the 3- and 4-positions of the isoquinoline moiety was successful (**4a–4c**). Aryl radical addition to 2-aminoquinoline (**4d**) occurs with retention of the free amine handle, delivering linchpins that drive derivatization in DEL-library settings.^{29,56} Of note, non-substituted heteroarenes, such as quinoline, were found to be reactive under the developed reaction conditions, but were excluded from our study for practical reasons because of the formation of regioisomers upon radical addition. Next, a palette of electron-rich pyrroles


(**4e, 4f, 4g, 4i, 5h, 6h**) as well as indoles (**4j–4q**) was investigated. Successful arylation was observed in the absence of nitrogen protecting groups. The method further facilitates the incorporation of multifunctional handles including esters (**4a, 4e, 4z**), nitriles (**4f, 4i, 4k, 4l, 4u**), ketones (**4g, 4o**), aldehydes (**4m, 4n**), and an amide (**4q**).

Medicinally-relevant scaffolds⁵⁷ including pyridazine (**4r**), pyrimidines (**4s, 6s**), as well as pyrazine (**6t**) were efficiently incorporated, underscoring the versatility of this photochemical heteroarylation. Furthermore, five-membered ring analogues such as thiophene (**4u**), benzothiazoles (**4v, 4w**), indazole (**4x**), benzimidazoles (**4y, 4z**), and imidazole (**4aa**) served as competent substrates under the developed conditions. In contrast, pyridine derivatives were found to be non-productive radical acceptors under the developed reaction conditions. Given the importance of peptides and their corresponding macrocycles in drug discovery efforts,^{58,59} the carbofunctionalization of tryptophan derivatives was examined. Under the developed conditions, effective C–H arylation of the electron-rich indole heterocycles in tryptophan–proline dipeptide **4ab** and monomeric tryptophan **6ad** was observed. In addition to free amine handles, *N*-Boc-proline moiety **4ab** was incorporated. These initial findings may present underexplored opportunities for the conjugation of peptide derivatives in DEL-settings using tryptophan as an efficient radical trap. Finally, the modification of biomolecules displaying higher degrees of molecular complexity, including caffeine (**4ac**) and dihydroquinine (**6ae**), proved successful. Contrary to these findings, derivatives of nucleobases, such as adenine or adenosine, showed no conversion in our hands. Of pertinent note, the ease of identification of reaction components in DEL synthesis is valuable for efficacious library composition. Under the developed photochemical heteroarylation, the corresponding DNA-bound, dehalogenated aryl subunit, stemming from C–X bond reduction followed by a rapid hydrogen atom transfer event, is typically observed as the major by-product in cases where the yield is compromised.⁶⁰ Finally, good regioselectivity with respect to aryl radical additions can be expected based on pre-cedented Minisci-type radical functionalizations.^{61–65}

To examine the influence of the halogenated aryl moiety toward the developed transformation, various DNA-bound headpieces (HPs) using pyrrole **2g** as an acceptor (Scheme 4, top) were examined. Aryl iodides (**1B, 1D, 1G, and 1H**) all served as competent substrates. Despite having an intrinsically higher reduction potential,⁵⁰ (hetero)aryl bromides (**1C, 1E, and 1F**) readily undergo reduction in the presence of the photocatalyst Ir(ppy)₃. Given the commercial availability of these building blocks, they serve as crucial feedstocks in drug discovery efforts and therefore are abundant in DEL libraries.⁶⁶

To validate the robustness of the method further, the reactivity of various HPs with selected heteroaryl BBs was examined (Scheme 4, bottom). Isoquinoline **5a** displayed good reactivity with a total of six different HPs (**1B, 1C, 1D, 1I, 1J, and 1K**). Notably, complete retention of the chloride handle in **1B** and **1K**, and similarly selective reduction of the C–I bond over the C–Br handle in **1J**, showcase the direct availability of electrophilic groups for subsequent cross-couplings. The C–H arylation of






Scheme 3 Evaluation of heteroarene scope. Conversion was determined by LC/MS analysis (see ESI†). Reaction conditions: DNA-conjugated aryl halide (1.0 equiv., 25 nmol), heteroarene (250 equiv., 6.25 μmol), Ir(ppy)₃ (0.5 equiv., 12.5 nmol), DIPEA (5.0 equiv., 125 nmol), 3 : 1 DMSO/H₂O (1.3 mM), 5 min irradiation with blue Kessil lamps ($\lambda_{\text{max}} = 456 \text{ nm}$, 40 W). ^a DNA-conjugated aryl halide derived from 4-chloro-3-iodo-benzoic acid (1B) was used. ^b DNA-conjugated aryl halide derived from 2-bromoisonicotinic acid (1C) was used. ^c Reaction was irradiated for 10 min.

indole-5-carboxaldehyde was further evaluated with a total of five different HPs (1E, 1I, 1J, 1K, and 1L) in comparable conversions. For the series employing iodo-chloro-substituted HP (1B), diverse functional groups were compatible, including ester 5a, free aniline 5d, nitriles 5i-l, ketone 5o, and phenol 5af. A different selection of BBs exhibited comparable reactivity using 2-bromoisonicotinic acid HP (1C, examples 6a-6ag). Remarkably, effective heteroarene radical addition to electron-deficient isoquinoline 2a was observed. This is likely a result of the pronounced nucleophilicity of pyridyl radicals in DMSO as the solvent.⁵⁴ Electron-rich pyrrolyl-, pyrazolyl-, or imidazolyl-halide derivatives were found to be non-productive substrates. Furthermore, the investigation of DNA-bound styrene system 11 demonstrates that the aryl radical additions occur exclusively to

the heteroarene in preference to the activated olefin. Overall, these findings demonstrate that myriad aryl halides on-DNA can be successfully reduced to achieve the direct C-H functionalization of electron-rich as well as electron-deficient heterocycles.

As the aryl radical intermediates generated in these transformations are highly reactive and potentially damaging to DNA, it was necessary to demonstrate that the integrity of the DNA remained intact during the indicated photochemical processes to ensure fidelity in the barcoding that relates the DNA sequence to the building blocks installed. To this end, a model DNA conjugate composed of an exemplary headpiece ligated to a 4-cycle tag and equipped with a 2-base 5' overhang was subjected to the standard reaction conditions under blue light irradiation. This model DNA conjugate was also reacted in the absence of either DIPEA,





Scheme 4 Evaluation of DNA-conjugated (hetero)aryl halides and heteroarenes. Conversion was determined by LC/MS analysis (see ESI†). Reaction conditions: DNA-conjugated aryl halide (1.0 equiv., 25 nmol), heteroaryl subunit (250 equiv., 6.25 μ mol), Ir(ppy)₃ (0.5 equiv., 12.5 nmol), DIPEA (5.0 equiv., 125 nmol), 3 : 1 DMSO/H₂O (1.3 mM), 5 min irradiation with blue Kessil lamps (λ_{max} = 456 nm, 40 W).

photocatalyst, or light. Upon completion of reactions under these conditions, these DNA conjugates were elongated by ligation to introduce the essential PCR primers and then quantified by qPCR. No substantial difference in qPCR amplification was observed across the various reaction samples, indicating DNA compatibility under the developed photochemical heteroarylation conditions (see ESI†).

Conclusion

In summary, a robust protocol for the direct C–H carbofunctionalization of heterocycles was achieved *via* the photo-reduction of DNA-bound halogenated aryl subunits. The reaction proceeds at room temperature and is completed within minutes of blue light illumination under open-to-air



conditions. The developed method is amenable to both electron-rich as well as electron-deficient medicinally-relevant heterocyclic building blocks, thereby expanding the chemical space available for DEL synthesis. This heteroarylation proceeds without the need for pre-functionalization of the heteroarene moiety or the presence of acidic additives, rendering this process suitable in DEL settings. Of note, electrophilic handles, including aryl chlorides, remain untouched during the course of the reaction, providing avenues for subsequent cross-couplings on-DNA. Furthermore, free alcohol and amine handles are tolerated, presenting opportunities for rapid library diversification. These findings demonstrate a general blueprint toward the synthesis of heteroaryl subunits, a complementary radical approach to traditional two-electron cross-coupling chemistry for C(sp²)-C(sp²) bond construction on-DNA.

Conflicts of interest

There are no conflicts to declare.

Data availability

Preparation of on-DNA substrates, synthesis of heteroarene derivatives, reaction workflow, procedures for photoinduced transformations, qPCR, PCR and sequencing data, NMR spectra, and UPLC/MS data have been uploaded as the ESI† material.

Author contributions

Dr Shorouk O. Badir conceived the topic. Dr Matthias Krumb, Dr Lisa Marie Kammer, Dr Shorouk O. Badir, and Dr Maria Jesús Cabrera-Alonso completed experiments with input from Professor Gary A. Molander. Dr Matthias Krumb, Dr Lisa Marie Kammer, and Dr Shorouk O. Badir prepared the manuscript with input from Professor Gary A. Molander and Dr Lisa A. Marcaurelle. All authors contributed to ideation and discussion of results.

Acknowledgements

The authors are grateful for financial support provided by NIGMS (R35 GM 131680 to G. M.) and GlaxoSmithKline. Dr Shorouk O. Badir is supported by the Bristol-Meyer-Squibb Graduate Fellowship for Synthetic Organic Chemistry. Dr María Jesús Cabrera-Afonso acknowledges the Fundación Ramón Areces for a postdoctoral fellowship. The NSF Major Research Instrumentation Program (award NSF CHE-1827457), the NIH supplement awards 3R01GM118510-03S1 and 3R01GM087605-06S1, as well as the Vagelos Institute for Energy Science and Technology supported the purchase of NMRs used in this study. We thank Dr Melissa C. Grenier-Davies (GSK), Dr Chris Dimitri (GSK), Dr Pradeep Bandaru (GSK), and Haleh Kazemi (GSK) for stimulating discussions. We thank Dr Charles W. Ross, III (UPenn) for mass spectral data. Johnson Matthey is acknowledged for donation of iridium(III) chloride

used in this study, and Kessil is thanked for the donation of lamps.

Notes and references

- 1 A. A. Shelat and R. K. Guy, *Nat. Chem. Biol.*, 2007, **3**, 442–446.
- 2 J. R. Broach and J. Thorner, *Nature*, 1996, **384**, 14–16.
- 3 A. Carnero, *Clin. Transl. Oncol.*, 2006, **8**, 482–490.
- 4 K. P. Mishra, L. Ganju, M. Sairam, P. K. Banerjee and R. C. Sawhney, *Biomed. Pharmacother.*, 2008, **62**, 94–98.
- 5 S. Brenner and R. A. Lerner, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 5381–5383.
- 6 P. R. Fitzgerald and B. M. Paegel, *Chem. Rev.*, 2021, **121**(12), 7155–7177.
- 7 D. Madsen, C. Azevedo, I. Micco, L. K. Petersen and N. J. V. Hansen, in *Prog. Med. Chem.*, ed. D. R. Witty and B. Cox, Elsevier, 2020, vol. 59, pp. 181–249.
- 8 D. Neri and R. A. Lerner, *Annu. Rev. Biochem.*, 2018, **87**, 479–502.
- 9 Y. Shi, Y.-r. Wu, J.-q. Yu, W.-n. Zhang and C.-l. Zhuang, *RSC Adv.*, 2021, **11**, 2359–2376.
- 10 M. Song and G. T. Hwang, *J. Med. Chem.*, 2020, **63**, 6578–6599.
- 11 A. L. Satz, J. Cai, Y. Chen, R. Goodnow, F. Gruber, A. Kowalczyk, A. Petersen, G. Naderi-Oboodi, L. Orzechowski and Q. Strebel, *Bioconjugate Chem.*, 2015, **26**, 1623–1632.
- 12 S. Patel, S. O. Badir and G. A. Molander, *Trends Chem.*, 2021, **3**, 161–175.
- 13 A. Mullard, *Nature*, 2016, **530**, 367–369.
- 14 P. A. Harris, B. W. King, D. Bandyopadhyay, S. B. Berger, N. Campobasso, C. A. Capriotti, J. A. Cox, L. Dare, X. Dong and J. N. Finger, *J. Med. Chem.*, 2016, **59**, 2163–2178.
- 15 A. Litovchick, C. E. Dumelin, S. Habeshian, D. Gikunju, M.-A. Guíé, P. Centrella, Y. Zhang, E. A. Sigel, J. W. Cuzzo and A. D. Keefe, *Sci. Rep.*, 2015, **5**, 1–8.
- 16 M. A. Clark, R. A. Acharya, C. C. Arico-Muendel, S. L. Belyanskaya, D. R. Benjamin, N. R. Carlson, P. A. Centrella, C. H. Chiu, S. P. Creaser and J. W. Cuzzo, *Nat. Chem. Biol.*, 2009, **5**, 647–654.
- 17 P. A. Harris, S. B. Berger, J. U. Jeong, R. Nagilla, D. Bandyopadhyay, N. Campobasso, C. A. Capriotti, J. A. Cox, L. Dare, X. Dong, P. M. Eidam, J. N. Finger, S. J. Hoffman, J. Kang, V. Kasparcova, B. W. King, R. Lehr, Y. Lan, L. K. Leister, J. D. Lich, T. T. MacDonald, N. A. Miller, M. T. Ouellette, C. S. Pao, A. Rahman, M. A. Reilly, A. R. Rendina, E. J. Rivera, M. C. Schaeffer, C. A. Sehon, R. R. Singhaus, H. H. Sun, B. A. Swift, R. D. Totoritis, A. Vossenkämper, P. Ward, D. D. Wisnoski, D. Zhang, R. W. Marquis, P. J. Gough and J. Bertin, *J. Med. Chem.*, 2017, **60**, 1247–1261.
- 18 R. K. Y. Cheng, C. Fiez-Vandal, O. Schlenker, K. Edman, B. Aggeler, D. G. Brown, G. A. Brown, R. M. Cooke, C. E. Dumelin, A. S. Doré, S. Geschwindner, C. Grebner, N.-O. Hermansson, A. Jazayeri, P. Johansson, L. Leong, R. Prihandoko, M. Rappas, H. Soutter, A. Snijder, L. Sundström, B. Tehan, P. Thornton, D. Troast,



- G. Wiggins, A. Zhukov, F. H. Marshall and N. Dekker, *Nature*, 2017, **545**, 112–115.
- 19 X. Huang, B. Ni, Y. Xi, X. Chu, R. Zhang and H. You, *Aging*, 2019, **11**, 12532–12545.
- 20 M. L. Malone and B. M. Paegel, *ACS Comb. Sci.*, 2016, **18**, 182–187.
- 21 D. K. Kölmel, R. P. Loach, T. Knauber and M. E. Flanagan, *ChemMedChem*, 2018, **13**, 2159–2165.
- 22 D. K. Kölmel, J. Meng, M.-H. Tsai, J. Que, R. P. Loach, T. Knauber, J. Wan and M. E. Flanagan, *ACS Comb. Sci.*, 2019, **21**, 588–597.
- 23 Z. Fan, S. Zhao, T. Liu, P.-X. Shen, Z.-N. Cui, Z. Zhuang, Q. Shao, J. S. Chen, A. S. Ratnayake, M. E. Flanagan, D. K. Kölmel, D. W. Piotrowski, P. Richardson and J.-Q. Yu, *Chem. Sci.*, 2020, **11**, 12282–12288.
- 24 A. Gironde-Martínez, D. Neri, F. Samain and E. J. Donckele, *Org. Lett.*, 2019, **21**, 9555–9558.
- 25 Y. Li, E. Gabriele, F. Samain, N. Favalli, F. Sladojevich, J. r. Scheuermann and D. Neri, *ACS Comb. Sci.*, 2016, **18**, 438–443.
- 26 S. O. Badir, J. Sim, K. Billings, A. Csakai, X. Zhang, W. Dong and G. A. Molander, *Org. Lett.*, 2020, **22**, 1046–1051.
- 27 J. P. Phelan, S. B. Lang, J. Sim, S. Berritt, A. J. Peat, K. Billings, L. Fan and G. A. Molander, *J. Am. Chem. Soc.*, 2019, **141**, 3723–3732.
- 28 D. K. Kölmel, A. S. Ratnayake and M. E. Flanagan, *Biochem. Biophys. Res. Commun.*, 2020, **533**, 201–208.
- 29 D. G. Brown and J. Boström, *J. Med. Chem.*, 2016, **59**, 4443–4458.
- 30 J.-L. Reymond and M. Awale, *ACS Chem. Neurosci.*, 2012, **3**, 649–657.
- 31 G. I. Stevenson, A. L. Smith, S. Lewis, S. G. Michie, J. G. Neduvilil, S. Patel, R. Marwood, S. Patel and J. L. Castro, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 2697–2699.
- 32 D. Chianelli, P. V. Rucker, J. Roland, D. C. Tully, J. Nelson, X. Liu, B. Bursulaya, E. D. Hernandez, J. Wu, M. Prashad, T. Schlama, Y. Liu, A. Chu, J. Schmeits, D. J. Huang, R. Hill, D. Bao, J. Zoll, Y. Kim, T. Groessl, P. McNamara, B. Liu, W. Richmond, I. Sancho-Martinez, A. Phimister, H. M. Seidel, M. K. Badman, S. B. Joseph, B. Laffitte and V. Molteni, *J. Med. Chem.*, 2020, **63**, 3868–3880.
- 33 Y. Ding, G. J. Franklin, J. L. DeLorey, P. A. Centrella, S. Mataruse, M. A. Clark, S. R. Skinner and S. Belyanskaya, *ACS Comb. Sci.*, 2016, **18**, 625–629.
- 34 H. Xu, F. Ma, N. Wang, W. Hou, H. Xiong, F. Lu, J. Li, S. Wang, P. Ma and G. Yang, *Adv. Sci.*, 2019, **6**, 1901551.
- 35 J. H. Hunter, L. Prendergast, L. F. Valente, A. Madin, G. Pairaudeau and M. J. Waring, *Bioconjugate Chem.*, 2020, **31**, 149–155.
- 36 N. A. Romero and D. A. Nicewicz, *Chem. Rev.*, 2016, **116**, 10075–10166.
- 37 M. H. Shaw, J. Twilton and D. W. C. MacMillan, *J. Org. Chem.*, 2016, **81**, 6898–6926.
- 38 J. W. Tucker and C. R. J. Stephenson, *J. Org. Chem.*, 2012, **77**, 1617–1622.
- 39 M. Reckenthäler and A. G. Griesbeck, *Adv. Synth. Catal.*, 2013, **355**, 2727–2744.
- 40 J. Xuan and W.-J. Xiao, *Angew. Chem., Int. Ed.*, 2012, **51**, 6828–6838.
- 41 F. Nicholas, G. Bassi, T. Zanetti, J. Scheuermann and D. Neri, *Helv. Chim. Acta*, 2019, **102**, e1900033.
- 42 W. F. Bailey and J. J. Patricia, *J. Organomet. Chem.*, 1988, **352**, 1–46.
- 43 N. M. Yoon, *Pure Appl. Chem.*, 1996, **68**, 843–848.
- 44 J. D. Nguyen, E. M. D'amato, J. M. Narayanam and C. R. Stephenson, *Nat. Chem.*, 2012, **4**, 854.
- 45 J. Chen, Y. Zhang, L. Yang, X. Zhang, J. Liu, L. Li and H. Zhang, *Tetrahedron*, 2007, **63**, 4266–4270.
- 46 Y. Wu, D. Kim and T. S. Teets, *Synlett*, 2021, DOI: 10.1055/a-1390-9065.
- 47 J. Tauber, D. Imbri and T. Opatz, *Molecules*, 2014, **19**, 16190–16222.
- 48 J. Zhang, J. Chen, X. Zhang and X. Lei, *J. Org. Chem.*, 2014, **79**, 10682–10688.
- 49 A. L. Beckwith and S. H. Goh, *J. Chem. Soc., Chem. Commun.*, 1983, 907.
- 50 I. Ghosh, T. Ghosh, J. I. Bardagi and B. König, *Science*, 2014, **346**, 725–728.
- 51 R. Aycock, D. Vogt and N. T. Jui, *Chem. Sci.*, 2017, **8**, 7998–8003.
- 52 R. Aycock, H. Wang and N. Jui, *Chem. Sci.*, 2017, **8**, 3121–3125.
- 53 J. I. Bardagi, I. Ghosh, M. Schmalzbauer, T. Ghosh and B. König, *Eur. J. Org. Chem.*, 2018, **2018**, 34–40.
- 54 A. J. Boyington, M.-L. Y. Riu and N. T. Jui, *J. Am. Chem. Soc.*, 2017, **139**, 6582–6585.
- 55 C. P. Seath, D. B. Vogt, Z. Xu, A. J. Boyington and N. T. Jui, *J. Am. Chem. Soc.*, 2018, **140**, 15525–15534.
- 56 P. Slobbe, E. Ruijter and R. V. Orru, *MedChemComm*, 2012, **3**, 1189–1218.
- 57 E. Vitaku, D. T. Smith and J. T. Njardarson, *J. Med. Chem.*, 2014, **57**, 10257–10274.
- 58 A. M. White and D. J. Craik, *Expert Opin. Drug Discovery*, 2016, **11**, 1151–1163.
- 59 Z. Zhu, A. Shaginian, L. C. Grady, T. O'Keeffe, X. E. Shi, C. P. Davie, G. L. Simpson, J. A. Messer, G. Evindar, R. N. Bream, P. P. Thansandote, N. R. Prentice, A. M. Mason and S. Pal, *ACS Chem. Biol.*, 2018, **13**, 53–59.
- 60 A. L. Satz, *ACS Comb. Sci.*, 2016, **18**, 415–424.
- 61 A. Arora and J. D. Weaver, *Org. Lett.*, 2016, **18**, 3996–3999.
- 62 A. S. Kyei, K. Tchabanenko, J. E. Baldwin and R. M. Adlington, *Tetrahedron Lett.*, 2004, **45**, 8931–8934.
- 63 M. M. Nebe, D. Loeper, F. Fürmeyer and T. Opatz, *Eur. J. Org. Chem.*, 2018, **2018**, 2471–2476.
- 64 J.-H. Ye, L. Zhu, S.-S. Yan, M. Miao, X.-C. Zhang, W.-J. Zhou, J. Li, Y. Lan and D.-G. Yu, *ACS Catal.*, 2017, **7**, 8324–8330.
- 65 E. C. Swift, T. M. Williams and C. R. J. Stephenson, *Synlett*, 2016, **27**, 754–758.
- 66 D. C. Blakemore, L. Castro, I. Churcher, D. C. Rees, A. W. Thomas, D. M. Wilson and A. Wood, *Nat. Chem.*, 2018, **10**, 383–394.

